Immuneering Corporation's stock is experiencing a decline today, despite receiving a reaffirmed "buy" rating from Chardan Capital with a price target of $13.00, suggesting a significant potential upside. However, the market seems to be reacting to a broader context of mixed analyst opinions. While Chardan Capital and Needham & Company LLC maintain a positive outlook, Morgan Stanley recently downgraded the stock to "underweight" on December 13th, which may be contributing to investor uncertainty.
The stock opened at $2.14 and has since dropped to $2.06, marking a 12.50% decrease from the previous close of $2.36. The trading volume has reached 1,879,706 shares, which is 82.20% of the average daily volume of 2,286,748, indicating active trading early in the day.